ArtFun+ is the most clinically validated & published technology for measuring arterial stiffness biomarkers by MRI.
If you are an experienced cardiovascular KOLs, interested in learning more about the medical potential of this software, IMAGEENS is offering a free trial, for a limited time period and a selection of KOLs only.
If you qualify for this offer, fill out the following form and we will be in touch with you shortly:
ArtFun+ measure arterial stiffness and flow biomarkers that are commonly recognized as a major risk factor for CV diseases and significant predictors of mortality and hard cardiovascular events.
The algorithms of ArtFun+ were used in the NIH-funded MESA trial (Multi-Ethnic Study of Atherosclerosis), which assessed the prognostic capability of the biomarkers measured by ArtFun+.
By measuring the Ascending Aorta Distensibility (AAD) from Phase Contrast (PC) MRIs in a cohort of 3’675 patients, the investigators of the MESA trial showed the predictive power of AAD for both patient survival and hard cardiovascular disease at 8.5 years.
AAD predicted the risk of mortality and hard cardiovascular events 8.5 years in advance – regardless of age. After adjusting for traditional cardiovascular risk s, individuals with a divergence between their distensibility and that of their age group had a two-time (2x) higher risk of death, and a four-fold (4x) higher risk of having a hard cardiovascular event.
Redheuil A, Bluemke DA, Lima JAC et. al. Proximal aortic distensibility is an independent predictor of all-cause mortality and incident CV events: the MESA study. J Am Coll Cardiol. 2014 Dec.
In addition to the leading biomarkers mentioned above, ArtFun+ enalbes a precise quantification multiple other geometrical and flow measurements, including: